GW Henssler & Associates Ltd. Sells 197,606 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Key Points

• GW Henssler & Associates Ltd. significantly reduced its stake in Zimmer Biomet Holdings, Inc. by 98.9% in Q1, leaving it with just 2,159 shares valued at approximately $244,000.
• Major institutional investors like Vanguard Group and Ameriprise Financial have increased their holdings, indicating ongoing interest despite the recent selling activities.
• Zimmer Biomet's stock has a current market cap of $21.02 billion and recently reported earnings that surpassed analysts' estimates, with a 7.0% year-over-year increase in revenue.

GW Henssler & Associates Ltd. decreased its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 98.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,159 shares of the medical equipment provider's stock after selling 197,606 shares during the quarter. GW Henssler & Associates Ltd.'s holdings in Zimmer Biomet were worth $244,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Janney Montgomery Scott LLC lifted its holdings in shares of Zimmer Biomet by 0.5% in the first quarter. Janney Montgomery Scott LLC now owns 25,647 shares of the medical equipment provider's stock valued at $2,903,000 after buying an additional 118 shares during the period. Curbstone Financial Management Corp lifted its holdings in shares of Zimmer Biomet by 3.4% in the first quarter. Curbstone Financial Management Corp now owns 4,266 shares of the medical equipment provider's stock valued at $483,000 after buying an additional 140 shares during the period. Brooklyn Investment Group lifted its holdings in shares of Zimmer Biomet by 45.9% in the first quarter. Brooklyn Investment Group now owns 461 shares of the medical equipment provider's stock valued at $52,000 after buying an additional 145 shares during the period. Roberts Wealth Advisors LLC lifted its holdings in shares of Zimmer Biomet by 0.8% in the first quarter. Roberts Wealth Advisors LLC now owns 18,497 shares of the medical equipment provider's stock valued at $2,093,000 after buying an additional 152 shares during the period. Finally, Wesbanco Bank Inc. lifted its holdings in shares of Zimmer Biomet by 0.8% in the first quarter. Wesbanco Bank Inc. now owns 20,012 shares of the medical equipment provider's stock valued at $2,265,000 after buying an additional 163 shares during the period. Institutional investors and hedge funds own 88.89% of the company's stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on ZBH. Evercore ISI cut their price objective on Zimmer Biomet from $102.00 to $96.00 and set an "in-line" rating for the company in a report on Tuesday, July 8th. UBS Group boosted their target price on Zimmer Biomet from $91.00 to $96.00 and gave the stock a "sell" rating in a research report on Friday, August 8th. Roth Capital reaffirmed a "buy" rating on shares of Zimmer Biomet in a research report on Thursday, August 7th. Canaccord Genuity Group cut their target price on Zimmer Biomet from $115.00 to $101.00 and set a "hold" rating on the stock in a research report on Monday, May 12th. Finally, Raymond James Financial boosted their target price on Zimmer Biomet from $104.00 to $113.00 and gave the stock an "outperform" rating in a research report on Friday, August 8th. Nine investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Zimmer Biomet has an average rating of "Hold" and an average target price of $111.00.

Insider Activity

In other news, insider Sang Yi sold 1,000 shares of the company's stock in a transaction dated Wednesday, June 11th. The stock was sold at an average price of $95.00, for a total transaction of $95,000.00. Following the completion of the sale, the insider owned 20,424 shares in the company, valued at approximately $1,940,280. This represents a 4.67% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 1.39% of the company's stock.

Zimmer Biomet Stock Up 0.8%

ZBH stock traded up $0.83 during mid-day trading on Friday, hitting $105.59. The stock had a trading volume of 1,168,434 shares, compared to its average volume of 1,287,856. The company has a current ratio of 1.87, a quick ratio of 0.96 and a debt-to-equity ratio of 0.54. Zimmer Biomet Holdings, Inc. has a 1-year low of $89.22 and a 1-year high of $114.72. The company has a fifty day moving average of $98.42 and a 200 day moving average of $99.64. The stock has a market capitalization of $20.92 billion, a price-to-earnings ratio of 25.69, a PEG ratio of 2.06 and a beta of 0.68.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share for the quarter, topping the consensus estimate of $1.98 by $0.09. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The company had revenue of $2.08 billion for the quarter, compared to analyst estimates of $2.06 billion. During the same period in the prior year, the firm posted $2.01 EPS. The business's revenue was up 7.0% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, equities analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be paid a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 0.9%. The ex-dividend date is Tuesday, September 30th. Zimmer Biomet's dividend payout ratio is 23.36%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.